IPO Guru
Bajaj
Closed Mainboard

Concord Biotech IPO

Concord Biotech IPO — date, price band, lot size & details 2023

Concord Biotech listed on 18 Aug 2023 at ₹900.05, 21.5% above the ₹741 issue price.

Concord Biotech is a biopharma company and one of the leading global makers of select fermentation-based APIs in immunosuppressants and oncology. Its total income was Rs 888.48 crore in FY2023.

Stock price

Concord Biotech is listed — here is the live share price.

Loading market data…
Abhishek Vohera, Founder of IPO Guru Researched & reviewed by Abhishek Vohera, Founder, IPO Guru Last updated Figures sourced from the RHP, BSE & NSE

Timetable

Key dates from opening to listing. Today is 17 November.

Key dates Listed
  1. Open 04 Aug 2023
  2. Close 08 Aug 2023
  3. Allotment 11 Aug 2023
  4. Refund/credit 14 Aug 2023
  5. Listing 18 Aug 2023

Issue summary

The terms of the offer, as filed.

IPO Dates 4 to 8 Aug, 2023
Price Band ₹705 – ₹741
Face Value ₹1
Lot Size 20 Shares
Issue Size ₹1550.52 Cr
Sale Type OFS only
Listing On BSE, NSE
Employee Discount Rs 70.00 per share
Registrar MUFG Intime India Private Limited
Min Investment ₹ 14,820
Reservation
QIB 50%
NII 15%
Retail 35%
Employee 0.05%

Share of the offer set aside for each investor category, as stated in the offer document.

What will it cost me?

Bidding is in multiples of 20 shares at the ₹741 cut-off. Drag to size your application.

shares
1 lot lots
If it lists at today's grey market premium of ₹67.67
on
Grey market premium is an unofficial, unregulated indicator. It is not a forecast.
Application Lots Shares Amount
Retail (min) 1 20 ₹14,820
Retail (max) 13 260 ₹1,92,660
S-HNI (min) 14 280 ₹2,07,480
S-HNI (max) 67 1,340 ₹9,92,940
B-HNI (min) 68 1,360 ₹10,07,760

Strengths & risks

Drawn from the offer document — the case for and against, side by side.

Strengths · 5

  • 01Total income rose from Rs 630.75 crore in FY2021 to Rs 888.48 crore in FY2023.
  • 02Profit after tax rose from Rs 174.93 crore in FY2022 to Rs 240.08 crore in FY2023.
  • 03The source puts the PAT margin at 28.14%.
  • 04Borrowing was low at Rs 31.24 crore on 31 March 2023, against net worth of Rs 1,290.00 crore.
  • 05It had over 200 customers in over 70 countries.

Risks · 5

  • 01The whole Rs 1,550.52 crore issue was offer for sale, so no money went to the company.
  • 02The P/E was 32.29 at the upper band of Rs 741, based on EPS of Rs 22.95.
  • 03Profit fell from Rs 234.89 crore in FY2021 to Rs 174.93 crore in FY2022, so results can swing.
  • 04API exports face strict regulatory inspections in markets such as the USA, and a few products drive much of the sales from its 23 APIs.
  • 05Promoters and the promoter group held only 44.08% before and after the issue.

Three years of numbers

All figures in ₹ crore, as reported in the Concord Biotech offer document.

Total income
888.48
631
736
888
31 Mar 202131 Mar 202231 Mar 2023
Profit after tax
240.08
235
175
240
31 Mar 202131 Mar 202231 Mar 2023
Borrowing vs net worth
31.24 / 1,290.00
31 Mar 202131 Mar 202231 Mar 2023
Borrowing Net worth
Metric 31 Mar 2023 31 Mar 2022 31 Mar 2021
Assets 1,513.98 1,312.80 1,182.55
Total Income 888.48 736.35 630.75
Profit After Tax 240.08 174.93 234.89
NET Worth 1,290.00 1,103.22 999.37
Total Borrowing 31.24 60.59 86.35

See how this IPO compares — view listing performance of all mainboard IPOs.

Valuation & key ratios

Ratios are for the latest full financial year reported in the Concord Biotech RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.

P/E Ratio
32.29
EPS (₹)
22.95
RoE
20.06%
RoCE
24.27%
RoNW
20%
PAT Margin
28.14%
NAV (₹)
123.31

Concord Biotech IPO Valuation

How the issue prices the company before and after the fresh shares are created.

Valuation Metric Pre-Issue Post-Issue
EPS (₹) ₹22.95 ₹22.95
P/E Ratio (x) 32.29 32.29
Market Cap at Offer Price (₹ Cr) ₹7,751.60 ₹7,751.60

Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹741 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.

Where the money goes

How the company intends to use the proceeds of the issue.

Information about the usage of proceeds from the Concord Biotech IPO will be updated shortly.

Concord Biotech IPO Anchor Investors

41 anchor investors across 25 fund houses committed ₹464.96 Cr a day before the issue opened.

Anchor Investor Fund House Shares Amount (₹ Cr) % of Anchor Book
Government Of Singapore Government Of Singapore 337,220 24.99 5.37%
ABU Dhabi Investment Authority - Stable ABU Dhabi Investment 303,480 22.49 4.84%
Government Pension Fund Global Government Pension Fund Global 303,480 22.49 4.84%
Polar Capital Funds Plc-Healthcare Opportunities Fund Polar Capital 303,480 22.49 4.84%
Ashoka India Opportunities Fund Ashoka 303,480 22.49 4.84%
HSBC Indian Equity Mother Fund HSBC 303,480 22.49 4.84%
Wf Asian Reconnaissance Fund Limited Wf Asian Reconnaissance 303,480 22.49 4.84%
Amundi Funds New Silk Road Amundi 303,480 22.49 4.84%
The Prudential Assurance Company Limited The Prudential Assurance 303,480 22.49 4.84%
Pinebridge Global Funds - Pinebridge India Equity Fund Pinebridge 303,480 22.49 4.84%
Nippon Life India Trustee Ltd-A/C Nippon India Small Cap Fund Nippon India Mutual Fund 189,660 14.05 3.02%
Nippon Life India Trustee Ltd-A/C Nippon India Pharma Fund Nippon India Mutual Fund 113,820 8.43 1.81%
Mirae Asset Healthcare Fund Mirae Asset Mutual Fund 303,480 22.49 4.84%
UTI - Healthcare Fund UTI Mutual Fund 151,740 11.24 2.42%
UTI Small Cap Fund UTI Mutual Fund 151,740 11.24 2.42%
DSP Healthcare Fund DSP Mutual Fund 303,480 22.49 4.84%
Franklin India Smaller Companies Fund Franklin Templeton Mutual Fund 236,040 17.49 3.76%
Franklin India Opportunities Fund Franklin Templeton Mutual Fund 67,440 5.00 1.07%
SBI Life Insurance Company Limited SBI Life Insurance 191,480 14.19 3.05%
Motilal Oswal Large And Midcap Fund Motilal Oswal Mutual Fund 191,515 14.19 3.05%
Edelweiss Trusteeship Co Ltd Ac - Edelweiss MF Ac - Edelweiss Large & Mid Cap Fund Edelweiss Mutual Fund 17,540 1.30 0.28%
Edelweiss Trusteeship Co Ltd Ac - Edelweiss MF Ac - Edelweiss Small Cap Fund Edelweiss Mutual Fund 24,300 1.80 0.39%
Edelweiss Focused Equity Fund Edelweiss Mutual Fund 36,360 2.69 0.58%
Edelweiss Trusteeship Co Ltd Ac - Edelweiss MF Ac - Edelweiss Long Term Equity Fund Edelweiss Mutual Fund 17,540 1.30 0.28%
Edelweiss Trusteeship Co Ltd Ac - Edelweiss MF Ac - Edelweiss Aggressive Hybrid Fund Edelweiss Mutual Fund 28,260 2.09 0.45%
Edelweiss Trusteeship Co Ltd Ac - Edelweiss MF Ac - Edelweiss Recently Listed Ipo Fund Edelweiss Mutual Fund 67,480 5.00 1.08%
Invesco India Flexi Cap Fund Invesco Mutual Fund 134,940 10.00 2.15%
Invesco India Equity & Bond Fund Invesco Mutual Fund 56,540 4.19 0.90%
Bandhan Emerging Businesses Fund Bandhan Mutual Fund 80,960 6.00 1.29%
Bandhan Midcap Fund Bandhan Mutual Fund 110,520 8.19 1.76%
Baroda BNP Paribas Large & Mid Cap Fund Baroda BNP Paribas Mutual Fund 191,480 14.19 3.05%
Aditya Birla Sun Life Insurance Company Limited Aditya Birla Sun Life Insurance 134,960 10.00 2.15%
Max Life Insurance Co. Ltd. - Pure Growth Fund Axis Max Life Insurance 16,180 1.20 0.26%
Max Life Insurance Co. Ltd. A/C Sustainable Equity Fund - Ulif02505/10/21 Sustainequ104 Axis Max Life Insurance 26,380 1.95 0.42%
Max Life Insurance Co. Ltd A/C Ulif01213/08/07Pensgrwsup104 - Pension Growth Super Fund Axis Max Life Insurance 32,380 2.40 0.52%
Max Life Insurance Co. Ltd. A/C Diversified Equity Fund (Ulif02201/01/20Lifediveqf104) Axis Max Life Insurance 60,020 4.45 0.96%
Bajaj Allianz Life Insurance Company Ltd Bajaj Allianz Life 134,960 10.00 2.15%
Tata Aia Life Insurance Company Limited A/C Emerging Opportunities Fund (Ulif 064 12/09/22 Eof 110) Tata Aia Life Insurance 60,720 4.50 0.97%
Tata Aia Life Insurance Company Limited A/C Small Cap Discovery Fund (Ulif 071 22/05/23 Scf 110) Tata Aia Life Insurance 33,740 2.50 0.54%
Tata Aia Life Insurance Company Limited A/C Life Whole Life Stable Growth Fund Ulif 011 04/01/07 Wls 110 Tata Aia Life Insurance 27,000 2.00 0.43%
Tata Aia Life Insurance Company Limited A/C Dynamic Advantage Equity Fund (Ulif 066 12/0/22 Daf 110) Tata Aia Life Insurance 13,500 1.00 0.22%
Total anchor allocation 464.96

Anchor investors bid a day before the issue opens and are locked in after allotment, so a book weighted towards domestic mutual funds is generally read as a stronger signal than one filled by short-horizon funds. Browse every anchor investor scheme or fund house we track.

About the company

Concord Biotech Limited was incorporated in 1984 and is based in India. As per the F&S report, it is one of the leading global developers and makers of select fermentation-based APIs across immunosuppressants and oncology by volume market share in 2022.

It makes APIs through fermentation and semi-synthetic processes, and also makes finished formulations. Its therapy areas include immunosuppressants, anti-bacterials, oncology and antifungals.

On 31 March 2023 it had 23 APIs and 77 approved products for formulations, and over 200 customers in over 70 countries, including the USA, Europe and Japan.

The IPO was Rs 1,550.52 crore and was entirely an offer for sale by Helix Investment Holdings, which sold its whole 20% stake. The company and the promoters received none of the money.

Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.

Promoters
Sudhir Vaid and Ankur Vaid
Promoter holding
44.08% → 44.08%
Pre-issue → post-issue

The bankers & the filings

Who is running the book, and the documents this page is built from.

Book-running lead manager
Kotak Mahindra Capital Company Limited View track record →
Book-running lead manager
Jefferies India Private Limited View track record →
Book-running lead manager
Citigroup Global Markets India Pvt. Ltd View track record →
Red Herring Prospectus
SEBI filing
Final offer document — price band, financials and risk factors. This page is built from it.
Open the RHP
Anchor allocation
Exchange filing
The anchor book as filed with the exchange a day before the issue opened.
Open the filing

Concord Biotech IPO Documents

Read the filings this page is built from.

Lead Manager Track Record

How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.

Listed in Profit 75.5% 154 of 204 listed
Avg Listing Gain +18.6% across 204 issues
Listed Below Issue 50 of 204 listed

Best listing: Premier Energies (+120.0%). Weakest: Puravankara Projects (-22.5%).

Listed in Profit 75% 30 of 40 listed
Avg Listing Gain +14.9% across 40 issues
Listed Below Issue 10 of 40 listed

Best listing: Nazara Technologies (+80.7%). Weakest: Turtlemint Fintech Solutions (-10.4%).

Listed in Profit 68.9% 51 of 74 listed
Avg Listing Gain +15.8% across 74 issues
Listed Below Issue 23 of 74 listed

Best listing: Tata Technologies (+140.0%). Weakest: Puravankara Projects (-22.5%).

Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.

Company contact

Company
Concord Biotech
Email

Frequently asked

What is the GMP of Concord Biotech?

The current Grey Market Premium is ₹67.67, or 9% over the issue price.

What is the Concord Biotech IPO price band?

₹705 to ₹741, on a face value of ₹1.

When is the allotment?

The basis of allotment is 11 August 2023, with listing on 18 August 2023.

How do I check allotment status?

On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.

Concord Biotech IPO

Every number here traces back to a filing.

IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.

Join the WhatsApp channel All mainboard IPOs

Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.

GMP
₹67.67
Subscribed
24.87×
Min bid
₹14,820
Size my application
Advertisement